Free Trial

Amalgamated Bank Sells 27,023 Shares of The Chemours Company (NYSE:CC)

Chemours logo with Basic Materials background

Amalgamated Bank lowered its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 37.2% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 45,691 shares of the specialty chemicals company's stock after selling 27,023 shares during the period. Amalgamated Bank's holdings in Chemours were worth $618,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in Chemours during the first quarter valued at $27,000. UMB Bank n.a. boosted its position in Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares during the last quarter. Quadrant Capital Group LLC grew its stake in shares of Chemours by 100.4% during the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after purchasing an additional 1,119 shares during the period. Farther Finance Advisors LLC grew its position in Chemours by 170.7% during the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 1,444 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Chemours in the 4th quarter worth $48,000. Hedge funds and other institutional investors own 76.26% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CC. The Goldman Sachs Group cut their target price on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, May 14th. Morgan Stanley dropped their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Royal Bank Of Canada increased their target price on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Thursday, July 3rd. Finally, UBS Group dropped their price target on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Chemours has a consensus rating of "Hold" and an average price target of $17.33.

Read Our Latest Analysis on CC

Chemours Trading Down 1.7%

Shares of NYSE CC traded down $0.24 during trading hours on Friday, reaching $13.81. The stock had a trading volume of 3,892,089 shares, compared to its average volume of 2,537,633. The Chemours Company has a 52-week low of $9.13 and a 52-week high of $25.54. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 69.05 and a beta of 1.65. The business's fifty day moving average price is $11.38 and its two-hundred day moving average price is $13.96. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). The firm had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a return on equity of 23.82% and a net margin of 0.54%. Chemours's quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 earnings per share. Analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were given a dividend of $0.0875 per share. This represents a yield of 3.17%. The ex-dividend date was Friday, May 16th. Chemours's dividend payout ratio (DPR) is 175.00%.

Insider Transactions at Chemours

In other Chemours news, CFO Shane Hostetter purchased 4,450 shares of the stock in a transaction dated Monday, May 19th. The stock was purchased at an average price of $11.28 per share, with a total value of $50,196.00. Following the transaction, the chief financial officer owned 59,694 shares of the company's stock, valued at approximately $673,348.32. This trade represents a 8.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Damian Gumpel acquired 13,400 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were acquired at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the completion of the acquisition, the insider owned 123,879 shares of the company's stock, valued at $1,142,164.38. This trade represents a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,672 shares of company stock worth $251,573 in the last three months. Insiders own 0.47% of the company's stock.

Chemours Profile

(Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Featured Stories

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

7 Nuclear Stocks One Announcement Away from Exploding

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines